This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
healthcare: Archive
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
ABTPositive Net Change NVONegative Net Change RMDPositive Net Change DXCMNegative Net Change EXASNegative Net Change TNDMNegative Net Change
cancer healthcare hospitals medical medical-devices oncology-screening pharmaceuticals thematic
How Should You Play UnitedHealth Stock Going Into Q1 Earnings?
by Kaibalya Pravo Dey
UNH's first-quarter earnings are likely to have benefited from growing premiums and service revenues.
UNHPositive Net Change HUMNegative Net Change MOHPositive Net Change
earnings-outlook earnings-preview healthcare hmo insurance medical
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
by Urmimala Biswas
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.
DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence computers healthcare iot medical medical-devices smart-health
UnitedHealth vs. Humana: Which Healthcare Stock Should You Buy Now?
by Kaibalya Pravo Dey
The CMS announced a hike in MA payments for fiscal year 2026, which will likely deliver a notable boost to UNH & HUM's bottom lines.
UNHPositive Net Change HUMNegative Net Change
healthcare hmo insurance insurance-premium medical
CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?
by Urmimala Biswas
CVS Health's strong track record of stable cash generation aids it amid the broader market sell-offs due to escalating 2025 Trump tariffs.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
by Urmimala Biswas
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change NVDAPositive Net Change TSLANegative Net Change
healthcare medical medical-devices
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
by Urmimala Biswas
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
china consensus-outlook earnings-estimates-revisions earnings-outlook healthcare medical medical-devices
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
by Urmimala Biswas
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
NVDAPositive Net Change MMSIPositive Net Change STXSPositive Net Change
artificial-intelligence healthcare medical medical-devices robotics saas semiconductor
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCPositive Net Change ACBPositive Net Change OGIPositive Net Change
cannabis healthcare marijuana marijuana-stocks medical
CVS Stock Soars 47% YTD: Is Digital Growth Fueling a Buy Opportunity?
by Urmimala Biswas
CVS Health is consistently increasing investments in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook healthcare medical medical-devices retail
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
by Urmimala Biswas
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
IRTCNegative Net Change SOPHNegative Net Change TEMPositive Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-streak healthcare medical medical-devices
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
by Urmimala Biswas
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-report healthcare medical medical-devices
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
by Urmimala Biswas
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
ABTPositive Net Change BSXPositive Net Change BDXNegative Net Change MDTPositive Net Change
earnings-outlook healthcare medical medical-devices
CVS Health Post-Q4 Earnings: Is the Stock Worth Buying Now?
by Urmimala Biswas
CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued growth in Health Services.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
UnitedHealth Pulls Back 11% in 3 Months: Think Twice Before Buying
by Kaibalya Pravo Dey
While UNH is pushing for a more efficient and cost-effective healthcare system, ongoing regulatory uncertainty and mounting cost pressures could keep the stock under check.
UNHPositive Net Change HUMNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
MDT Stock Trades Cheaper Than Peers Ahead of Q3 Earnings: Time to Buy?
by Urmimala Biswas
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
healthcare medical medical-devices
SOUN Stock Skyrockets 866% in a Year: Should You Buy, Sell or Hold?
by Nida Ali Saigal
SoundHound AI benefits from strong partnerships and innovative Voice AI tech to drive growth, but high valuations and near-term losses pose challenges.
CMGPositive Net Change REKRPositive Net Change LCIDPositive Net Change SOUNNegative Net Change
artificial-intelligence automobiles healthcare restaurants tech-stocks
CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?
by Urmimala Biswas
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
Brian's Big Idea: Healthcare Stocks
by Brian Bolan
Look at 3 healthcare stocks and the Healthcare Innovators service at Zacks.com.
VCYTNegative Net Change BBIOPositive Net Change HIMSPositive Net Change
healthcare
CVS Stock Trades Near 52-Week Low: Should You Buy the Dip?
by Urmimala Biswas
CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
CVS' High Utilization & MBR to Cut 2024 Profits: Is the Stock a Sell?
by Urmimala Biswas
The persistently elevated utilization of medical services is significantly putting pressure on CVS Health's Health Care Benefits segment.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
CVS Q3 Estimates Plunge Before Earnings Release: How to Play the Stock
by Urmimala Biswas
CVS Health faces outpatient and supplemental benefits pressure within Health Care Benefits.
CVSPositive Net Change HLFPositive Net Change WBANegative Net Change
healthcare medical retail
Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?
by Kaibalya Pravo Dey
Looking ahead to 2025, UNH projects adjusted earnings to reach around $30 per share at the top end, which falls short of the Zacks Consensus Estimate.
UNHPositive Net Change HUMNegative Net Change ELVNegative Net Change
earnings-outlook healthcare hmo medical
Is Humana a Deep Value Stock to Buy?
by David Bartosiak
Humana shares have fallen from over $560 to under $250. Could now be the time to buy?
HUMNegative Net Change
healthcare stock-performance
Is CVS Health Stock Finally a Value Buy?
by David Bartosiak
Value traps are dangerous. Buying a stock just because it is down well off its highs does not always work out.
CVSPositive Net Change
healthcare